Elanco Animal Health Inc
F:5EA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Elanco Animal Health Inc
F:5EA
|
US |
|
O
|
O'Reilly Automotive Inc
LSE:0KAB
|
US |
|
A
|
Amgen Inc
XHAM:AMG
|
US |
|
C
|
Coinbase Global Inc
F:1QZ
|
US |
|
S
|
Safran SA
F:SEJ1
|
FR |
|
UltraTech Cement Ltd
BSE:532538
|
IN |
|
C
|
Caterpillar Inc
DUS:CAT1
|
US |
Elanco Animal Health Inc
Elanco Animal Health makes medicines and health products for animals. It sells prescription drugs, vaccines, and parasite control products for pets and farm animals. The company’s main customers are veterinarians, pet owners, livestock producers, and animal health distributors that buy its products and pass them on to end users. Elanco earns money by selling these animal care products through clinics, retailers, distributors, and agricultural channels. Its business is tied to the ongoing need to prevent disease, treat illness, and support animal health rather than one-time purchases of equipment or services. That gives it a recurring, product-based revenue model that depends on pets needing routine care and farms needing healthier animals. What makes Elanco’s role distinct is that it sits between drug research and day-to-day animal care. It develops and markets treatments that help keep companion animals healthy and livestock productive, so it serves both the pet market and the food-animal supply chain. This puts the company in a specialized corner of healthcare where demand is driven by veterinary practice, animal ownership, and the economics of farming.
Elanco Animal Health makes medicines and health products for animals. It sells prescription drugs, vaccines, and parasite control products for pets and farm animals. The company’s main customers are veterinarians, pet owners, livestock producers, and animal health distributors that buy its products and pass them on to end users.
Elanco earns money by selling these animal care products through clinics, retailers, distributors, and agricultural channels. Its business is tied to the ongoing need to prevent disease, treat illness, and support animal health rather than one-time purchases of equipment or services. That gives it a recurring, product-based revenue model that depends on pets needing routine care and farms needing healthier animals.
What makes Elanco’s role distinct is that it sits between drug research and day-to-day animal care. It develops and markets treatments that help keep companion animals healthy and livestock productive, so it serves both the pet market and the food-animal supply chain. This puts the company in a specialized corner of healthcare where demand is driven by veterinary practice, animal ownership, and the economics of farming.
Beat and raise: Elanco reported 8% organic constant currency revenue growth in Q2, topping guidance and prompting management to raise full-year outlook for revenue, EBITDA and EPS.
Innovation led: Zenrelia and Credelio Quattro were the biggest growth drivers, while Befrena showed very early demand that was described as stronger than expected.
Margins improved: Gross margin expanded 80 basis points to 58.1%, and management said productivity, mix and Elanco Ascend are helping offset inflation and support further margin gains.
Leverage falling faster: Net leverage reached 3.1x in Q2, and Elanco now expects to end the year at about 3x, better than prior plans.
Pricing resilient: Management said pricing remains responsible across the market, with U.S. pet health pricing accelerating and expected to keep improving in the second half.
Longer runway: The company said its Big 6 innovation products are still early in their growth curves, with significant room ahead in both U.S. and international markets.